Gujarat Kidney Super Speciality Ltd vs Nephrocare Health Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Nephrocare Health Services Ltd changed from 66 on March 2026 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 3 yearsThe Market Cap of Nephrocare Health Services Ltd changed from ₹ 5072 crore on March 2026 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 3 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Nephrocare Health Services Ltd for the Jun '26 is ₹ 289.21 crore as compare to the Mar '26 revenue of ₹ 277.18 crore. This represent the growth of 4.34% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Nephrocare Health Services Ltd for the Jun '26 is ₹ 67.78 crore as compare to the Mar '26 ebitda of ₹ 62.24 crore. This represent the growth of 8.9% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 8 quarters. This represents a CAGR of 34.06% The net profit of Nephrocare Health Services Ltd changed from ₹ 20.11 crore to ₹ 31.97 crore over 7 quarters. This represents a CAGR of 30.33% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Nephrocare Health Services Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 6 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Nephrocare Health Services Ltd

Nephrocare Health Services Limited was incorporated as 'Nephrocare Health Services Private Limited', a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company was converted into a public limited company and the name was changed to 'Nephrocare Health Services Limited' with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy.
The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad.
It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Nephrocare Health Services Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Nephrocare Health Services Ltd is 6,193 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd?

As of October 31, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Nephrocare Health Services Ltd stock price is INR ₹615.95.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Nephrocare Health Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.